FDA Greenlights Drugs to Battle Screwworms in Cats and Dogs
Published Date: 12/29/2025
Notice
Summary
The FDA just gave the green light for two new emergency animal drugs to treat nasty New World screwworm infections in dogs, puppies, cats, and kittens. These quick-acting treatments are now officially authorized as of late 2025 to help protect pets from this serious health threat. Pet owners and vets can expect faster access to these lifesaving drugs without extra costs right now.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
EUA for Dog Screwworm Treatment
The FDA issued an Emergency Use Authorization (EUA) to Elanco US Inc. for Credelio (lotilaner) to treat New World screwworm (NWS) infestations in dogs and puppies. This authorization is effective October 24, 2025 and allows emergency use and introduction into interstate commerce under the FD&C Act section 564.
EUA for Cat Screwworm Treatment
The FDA issued an Emergency Use Authorization (EUA) to Elanco US Inc. for Credelio CAT (lotaliner) to treat New World screwworm (NWS) infestations in cats and kittens. This authorization is effective November 21, 2025 and allows emergency use and introduction into interstate commerce under the FD&C Act section 564.
Faster Access to Pet Treatments Now
The notice states that pet owners and veterinarians can expect faster access to these lifesaving drugs for New World screwworm and that this access is available without extra costs right now. The two EUAs became effective October 24, 2025 and November 21, 2025, respectively.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20441, Medical Devices; Cardiovascular Devices; Classification of the Hyperoxia Monitoring Device Adjunct to Pulse Oximetry
The FDA is officially putting the hyperoxia monitoring device that works with pulse oximeters into a safer, easier-to-manage category called Class II. This change, effective October 6, 2026, means the device will have special safety rules but fewer regulatory hurdles, helping patients get access to this cool tech faster. Medical device makers and healthcare providers will feel the impact, with smoother approval processes and no big new costs expected.
Previous / Next Documents
Previous: 2025-23913, Carbon and Certain Alloy Steel Wire Rod From China; Determinations
The U.S. government decided to keep special taxes on carbon and certain alloy steel wire rod imported from China because removing them could hurt American steel makers. These taxes help protect U.S. jobs and businesses from unfair competition. This decision was finalized at the end of 2025 and means importers will keep paying these extra fees for now.
Next: 2025-23952, Sunshine Act Meetings
The National Council on Disability is holding a two-day meeting in January 2026, both in Orlando and online, to discuss important issues like youth in nursing homes, disaster experiences, and accessible transportation. This meeting affects people with disabilities, especially in Florida, and aims to improve policies and services. No new costs are mentioned, but the event invites public input and shares updates on ongoing projects.